ACTG2 Inhibits Growth and Is Epigenetically Repressed in Small Intestinal Neuroendocrine Tumors Abstract #820

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) originate from the enterochromaffin cells in the ileum. Actin gamma smooth muscle 2 (ACTG2) is downregulated in lymph node metastases from SI-NETs. ACTG2 and microRNA-145 (miR-145) are aberrantly expressed in other cancers and ACTG2 can be induced by miRNA-145.
Aim(s): To investigate the cause for downregulation and function of ACTG2 in SI-NETs.
Materials and methods: ACTG2 protein expression was analyzed in SI-NETs (n=24) by immunohistochemistry. The SI-NET cell line CNDT2.5 was treated with 3-deazaneplanocin (DZNep), a selective EZH2 inhibitor (EPZ-6438) and a DNA hypomethylating agent (5-aza-dC). Cells were transfected with ACTG2 plasmid and miR-145. Western blotting analysis, qRT-PCR, colony-forming and viability assays were performed, and miR-145 expression levels measured in tumor samples (n=24).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: PhD candidate Katarina Edfeldt

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1278 Midkine is a New Novel Serum Biomarker in Small Intestinal Neuroendocrine Tumors (SI-NETs).
Introduction: SI-NETs are often diagnosed late, which limits curative treatment options.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Kosmas Daskalakis
Keywords: Biomarker, SI-NET
#1645 A Role of TETs and 5-Hydroxymethylcytosine in SI-NETs
Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing neoplasms. Identification of patients with worse outcome and of novel potential targets for therapy is important goals. The epigenetic mark 5-hydroxymethylcytosine (5-hmC) is severely reduced in various cancers and was recently found by us to discriminate between parathyroid adenoma and carcinoma. A growth regulatory role of TET1 was also found.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: PhD student Elham Barazeghi
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#676 Gene Silencing by Promoter Hypermethylation in SI-NETs
Introduction: Aberrant DNA methylation is an important feature of human cancer affecting corresponding gene expressions and clinical features in different tumors, including SI-NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Omid Fotouhi
Keywords: SI-NET
#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)
Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Sonja Levy
Keywords: SI-NET, Nomogram, Survival